Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cytokine Release Assay Favored for Latent TB in Pregnancy

By LabMedica International staff writers
Posted on 16 Jul 2012
The interferon-gamma release assay (IGRA) blood test for tuberculosis diagnosis is more specific in pregnant women and may be a better predictor of disease progression.

Although IGRAs are currently recommended over skin testing for pregnant women with risk factors for exposure to Mycobacterium tuberculosis, the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) recommendations were made without data on IGRA performance during pregnancy.

Doctors at the New York University School of Medicine (NY, USA) analyzed the performance of the IGRA blood test in 140 pregnant and 140 nonpregnant adolescents and women receiving care at public hospital outpatient clinics. About 90% had at least one risk factor for exposure to M. tuberculosis. All but three of the 103 pregnant women and adolescents who had negative Mantoux tuberculin skin test results also had negative IGRA, and the overall agreement between tuberculin skin test and IGRA results was 88% for all pregnant patients.

The IGRA kit used in the study was the QuantiFERON-TB Gold In Tube assay (Cellestis; Valencia, CA, USA). Only 12 of the 28 women (43%) with positive skin test results had positive IGRA results and five of them had received the Bacillus Calmette-Guérin (BCG) vaccine. The proportion of pregnant patients with a positive IGRA increased with the likelihood of exposure to M. tuberculosis, and no one without a known risk factor for M. tuberculosis had a positive result on either test. Interferon-gamma levels did not differ significantly during any trimester of pregnancy. None of the 25 women who underwent repeated IGRA testing during their pregnancy or postpartum converted from negative to positive or vice versa. IGRA results did not differ significantly between the pregnant and nonpregnant patients in the study.

Jennifer Lighter-Fisher, MD, a coauthor of the study, said, "IGRAs cost between USD 30 to USD 60 a test, which is much more expensive than a skin test, but the higher cost would be offset by greater efficiency. In our study, we observed less than half of the women with positive skin tests had a positive IGRA. Therefore, the additional cost of IGRAs is offset by a decrease in the number of positive test results and the associated costs of evaluating and treating tuberculin skin test-positive patients. If the IGRAs were to be used instead of the skin test during pregnancy, far fewer women will be identified as positive and therefore would have avoided a chest X-ray during pregnancy and a nine-month regimen of anti-TB medication." The study was published in the June 2012 issue of Obstetrics and Gynecology.

Related Links:

US Centers for Disease Control and Prevention
New York University School of Medicine
Cellestis



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.